Healthcare Provider

Patients can experience HIV-associated wasting (HIVAW) even when the virus is well-controlled with antiretroviral therapy (ART)¹

The prevalence of HIVAW is 3.1% annually, even among those taking ART¹

In contrast to the pre-ART era, HIVAW may also occur among PWH who are virologically suppressed²

Key characteristics of HIVAW or cachexia, also known as HIV-associated weight loss (HAWL)^3,4

Loss of Lean Body Mass

Unintentional Weight Loss

Decreased Physical Endurance

Updating terminology to reflect modern-day phenotypes of HIVAW

The clinical presentation of HIVAW has changed since the pre-ART era.^1,5-7

HAWL has been proposed as an appropriate term for patients who have experienced unintended weight loss who are on antiretroviral therapy⁴
As with HIVAW or cachexia, HAWL represents continuous, unintentional weight loss that would not be better explained by another concurrent illness of condition beyond HIV infection itself⁴

Explore the latest information on HIVAW and other helpful resources

Pathogenesis

The causes of HIVAW are complicated and multifactorial. Learn more about the pathogenesis of this syndrome.

Real-world Evidence

HIVAW is still prevalent in the United States, even in the modern ART era. See the latest real-world evidence.

Diagnosis

Learn about the symptoms your patients may be experiencing so that you can recognize the signs and begin diagnosing HIVAW.

Treatment Options

See the current treatment options available for HIVAW.

Resources & Videos

Explore a robust library of downloadable PDF resources and videos about HIVAW.

The people depicted on this website are not actual healthcare providers or patients with HIV-associated wasting.

References: 1. Siddiqui J, Samuel S, Hayward B, et al. HIV-associated wasting prevalence in the era of modern antiretroviral therapy. AIDS. 2022;36:127-135. 2. Mounzer K, Brunet L, Hsu R, et al. Changes in body mass index associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States. AIDS Res and Human Retroviruses. 2021;37(11)852-861. 3. Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA. Counteracting muscle wasting in HIV-infected individuals. HIV Med. 2006;7(5):299-310. 4. Siddiqui J, Phillips AL, Freedland ES, Sklar AR, Darkow T, Harley CR. Prevalence and cost of HIV-associated weight loss in a managed care population. Curr Med Res Opin. 2009;25(5):1307-1317. 5. Gelato M, McNurlan M, Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther. 2007;29(11):2269-2288. 6. Siddiqui J, Samuel S, Hayward B, et al. The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy. J Manag Care Spec Pharm. 2022;20(10):1180-1189. 7. Wanke C, Kotler D, and the HIV Wasting Collaborative Consensus Committee. Collaborative Recommendations: The approach to diagnosis and treatment of HIV wasting. J Acquir Immune Defic Syndr. 2004;37(S5):S284-S288.

UNDERSTANDING HIV-ASSOCIATED WASTING IN THE MODERN ART ERA

Patients can experience HIV-associated wasting (HIVAW) even when the virus is well-controlled with antiretroviral therapy (ART)¹

The prevalence of HIVAW is 3.1% annually, even among those taking ART¹

Key characteristics of HIVAW or cachexia, also known as HIV-associated weight loss (HAWL)^3,4

Updating terminology to reflect modern-day phenotypes of HIVAW